China-based trial with 108 patients finds meplazumab, a CD147 antibody, lowered 28-day mortality in severe COVID-19 from 15.4% to 3.9% in supplementary analysis, showing promise as a safe, host-targeted antiviral therapy.

www.nature.com/articles/s41...

Severe #COVID19 remains a major clinical concern. This phase 3 trial shows that meplazumab, a CD147 antibody, demonstrated a favorable safety profile and improved clinical outcomes, supporting its therapeutic potential.

#STTT #OpenAccess: doi.org/10.1038/s413...

#InfectiousDiseases #Immunotherapy

This study shows #SARSCoV2 upregulates #CD147, driving extended infection and immune imbalance; #Meplazumab blocks CD147–spike interaction, restores immune balance, and mitigates severe #COVID19, highlighting CD147 as a therapeutic target.

#OpenAccess #STTT: doi.org/10.1038/s413...

#SARSCoV2 triggers AHR‑mediated #CD147 up‑regulation, reduces ACE2, and drives immune imbalance through #M2macrophage signaling, while #Meplazumab disrupts CD147‑spike binding, restores immune balance, and mitigates severe #COVID19.

#OpenAccess in #STTT: doi.org/10.1038/s413...

This phase 3 trial shows that the #humanized #CD147 antibody #meplazumab significantly lowered 14, 28, and 56-day mortality, rapidly reduced #viralload, and improved multiple clinical outcomes in severe #COVID19 patients. #medsky

#STTT #OpenAccess: doi.org/10.1038/s413...

Schweres #COVID19 bleibt ein großes klinisches Problem. Diese Phase-3-Studie zeigt, dass Meplazumab, ein CD147-Antikörper, ein günstiges Sicherheitsprofil und verbesserte klinische Ergebnisse zeigte, was sein therapeutisches Potenzial unterstützte.

Meplazumab, a CD147 antibody, for severe COVID-19: a double-blind, randomized, placebo-controlled, phase 3 clinical trial
->Nature | #Covid19 | More info from EcoSearch

Meplazumab, a CD147 antibody, for severe COVID-19: a double-blind, randomized, placebo-controlled, phase 3 clinical trial https://pubmed.ncbi.nlm.nih.gov/40222976/

A phase 3 #ClinicalTrial evaluating efficacy of #Meplazumab, a humanized CD147 antibody, revealed that it reduces mortality and enhances clinical benefits with a good safety profile in severe #COVID19 patients.

#OpenAccess: doi.org/10.1038/s413...